ATRC

Atricure, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000

$61.25Close $3.0BMarket cap $25.86 – $62.4852-week range Nov 3, 2026Next report · after the close

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 96 · stronger than 96% of stocks over 12 months
Near its high 2% below its 52-week high
Volume drying up last 10 days 40% under the 50-day average

Cautions

Results soon Nov 3, 2026, in 2 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Jul 27, 2026

Off 12-month high 2%

1wk 3.9% price change

1mo 9.0% price change

12-month return 80% market up 11% · its own up 62%

F-score 6 / 9 Mixed

Altman Z 11.61 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 6.2× price / book

Earnings yield 0.3% EBIT / enterprise value

Cheaper than 28% of the market · expensive

Revenue growth 15% year on year

EPS growth — latest quarter

Sales growth 13% latest quarter · -1 pts

ROE 2% return on equity

Free cash margin 9% $48.3M FCF

D/E 0.13 long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

not yet profitable on its assets
took on more long-term debt
issued more shares
generating cash from operations
profitability improving
profits backed by cash
short-term liquidity improved
gross margin widened
assets working harder

Trade setup

ATR% 3.5% $2.13 a day · 2×ATR $56.99

RS 96 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.9× vs 50-day average

Up/down volume 0.96 50 sessions

Implied move — no option chain · report Nov 3, 2026

Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Jul 23, 2026

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $534.5M +15% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$11.4M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $48.3M +6381% on FY2024

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Gross 75%
Net -2%
Free cash 9%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $105.6M net cash

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 49.79m +9.8% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$206.5M	$274.3M	$330.4M	$399.2M	$465.3M	$534.5M
Gross margin	72%	75%	74%	75%	75%	75%
Operating income	-$44.2M	$55.2M	-$42.7M	-$26.7M	-$40.0M	-$9.4M
Net income	-$48.2M	$50.2M	-$46.5M	-$30.4M	-$44.7M	-$11.4M
Net margin	-23%	18%	-14%	-8%	-10%	-2%
Earnings per share	-$1.14	$1.09	-$1.02	-$0.66	-$0.95	-$0.24
Free cash flow	-$25.1M	-$23.5M	-$39.0M	-$7.5M	$745,000	$48.3M
Free cash margin	-12%	-9%	-12%	-2%	0%	9%
Cash	$41.9M	$43.7M	$58.1M	$84.3M	$122.7M	$167.4M
Long-term debt	$53.4M	$59.7M	$56.8M	$60.6M	$61.9M	$61.9M
Shareholders' equity	$412.4M	$483.8M	$456.8M	$466.2M	$461.0M	$491.9M
Shares outstanding	45.35m	46.02m	46.56m	47.53m	48.87m	49.79m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Jul 27, 2026	Quarterly ↗	Jun 30, 2026	27d
May 6, 2026	Quarterly ↗	Mar 31, 2026	36d
Feb 19, 2026	Annual ↗	Dec 31, 2025	50d
Oct 30, 2025	Quarterly ↗	Sep 30, 2025	30d
Jul 30, 2025	Quarterly ↗	Jun 30, 2025	30d
Apr 30, 2025	Quarterly ↗	Mar 31, 2025	30d
Feb 14, 2025	Annual ↗	Dec 31, 2024	45d
Oct 30, 2024	Quarterly ↗	Sep 30, 2024	30d
Jul 31, 2024	Quarterly ↗	Jun 30, 2024	31d
May 2, 2024	Quarterly ↗	Mar 31, 2024	32d
Feb 16, 2024	Annual ↗	Dec 31, 2023	47d
Nov 2, 2023	Quarterly ↗	Sep 30, 2023	33d

Current reports

Filed	Disclosed
Jul 23, 2026	Results ↗
May 19, 2026	Director or officer change · Shareholder vote ↗
May 5, 2026	Results ↗
Feb 17, 2026	Results ↗
Jan 12, 2026	Material agreement · Results · New obligation ↗
Oct 29, 2025	Results ↗
Jul 29, 2025	Results ↗
May 20, 2025	Director or officer change · Shareholder vote ↗
Apr 29, 2025	Results ↗
Mar 26, 2025	Regulation FD ↗
Feb 12, 2025	Results ↗
Jan 13, 2025	Results · Regulation FD ↗